KPTI - Karyopharm Therapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart

KPTI is currently covered by 5 analysts with an average price target of $13.67. This is a potential upside of $13.65 (68250%) from yesterday's end of day stock price of $0.02.

Karyopharm Therapeutics's activity chart (see below) currently has 138 price targets and 152 ratings on display. The stock rating distribution of KPTI is 83.33% BUY and 16.67% HOLD.

Stock Analyst Price Targets - Review

Analysts' price targets on this stock were met 44.84% of the time, taking 311.96 days on average.

Highest price target for KPTI is $28, Lowest price target is $3, average price target is $13.67.

Most recent stock forecast was given by EDWARD TENTHOFF from PIPER SANDLER on 31-Jul-2026. First documented stock forecast 02-Jun-2015.

Currently out of the existing stock ratings of KPTI, 2 are a HOLD (16.67%), 10 are a BUY (83.33%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 09-Oct-2025

$7

$5.38 (332.10%)

3 months 17 days ago
(31-Jul-2026)

0/3 (0%)

$5.08 (264.58%)

Buy Since 18-Feb-2026

$3

$1.38 (85.19%)

3 months 17 days ago
(31-Jul-2026)

0/3 (0%)

$1.08 (56.25%)

Buy Since 03-Nov-2023

$15

$4.79 (46.91%)

$21

7 months 23 days ago
(25-Mar-2026)

3/5 (60%)

$9.79 (187.91%)

1410

Buy Since 10-Mar-2026

$28

$22.52 (410.95%)

$330

8 months 7 days ago
(10-Mar-2026)

1/2 (50%)

$19.77 (240.22%)

1085

Buy Since 12-Apr-2023

$19

$33

1 years 13 days ago
(04-Nov-2025)

10/19 (52.63%)

$13.35 (236.28%)

277

Show more analysts

Please expand the browser size to see the chart

What is KPTI (Karyopharm Therapeutics) average time for price targets to be met?

On average it took 312 days for the stock forecasts to be reached, with an average price target met ratio of 44.84%.

Which analyst most recently updated their price target on KPTI (Karyopharm Therapeutics)?

Edward Tenthoff

Which analyst has the most public recommendations on KPTI (Karyopharm Therapeutics)?

Edward Tenthoff works at PIPER SANDLER and has 38 price targets and 25 ratings on KPTI

Which analyst is the currently most bullish on KPTI (Karyopharm Therapeutics)?

Maury Raycroft with the highest potential upside of $523.38

Which analyst is the currently most reserved on KPTI (Karyopharm Therapeutics)?

Jonathan Chang with the lowest potential downside of -$4.21
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

To continue looking at analysts data please register to the advanced membership

What is AnaChart?